The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Issue of Equity and Total Voting Rights

28 Feb 2019 10:35

RNS Number : 4338R
Instem plc
28 February 2019
 

Instem plc("Instem" or the "Company")

Issue of Equity and Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, following the exercise of share options, 93,713 new ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.

Application will be made to the London Stock Exchange for the admission of the 93,713 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 6 March 2019.

Total Voting Rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital will comprise 16,246,983 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company will be 16,246,983.

The figure of 16,246,983 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley, Corporate Finance

 

Rachel Hayes, Corporate Broking

 

 

 

 

 

 

 

Walbrook Financial PR

 

Paul Cornelius

+44 (0) 20 7933 8780

Sam Allen

instem@walbrookpr.com

Nick Rome

 

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit instem.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAEAPADANEFF

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.